FibroBiologics Inc. Files Amendment No. 5 to S-1 Registration Statement

TL;DR

<b>FibroBiologics, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities for public sale.</b>

AI Summary

FibroBiologics Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on January 12, 2024. FibroBiologics, Inc. filed Amendment No. 5 to its Form S-1 Registration Statement on January 12, 2024. The company is incorporated in Delaware and has its principal executive offices in Houston, Texas. The filing relates to a registration of securities under the Securities Act of 1933. FibroBiologics, Inc. is classified as a Pharmaceutical Preparations company. The company is identified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Why It Matters

For investors and stakeholders tracking FibroBiologics Inc., this filing contains several important signals. This amendment signifies continued progress in the company's path towards a potential public offering, which could provide access to capital for growth and development. As an emerging growth company and smaller reporting company, FibroBiologics may benefit from certain regulatory accommodations, but also faces scrutiny regarding its financial reporting and operational plans.

Risk Assessment

Risk Level: medium — FibroBiologics Inc. shows moderate risk based on this filing. The company is filing an S-1/A, which is a registration statement for an IPO or follow-on offering. The success of such an offering is subject to market conditions and investor appetite, and the company's specific business prospects, which are not detailed in this filing.

Analyst Insight

Monitor future filings for details on the offering size, pricing, and use of proceeds to assess the potential impact on the company's capital structure and growth trajectory.

Key Numbers

• 2024-01-12 — Filing Date (Amendment No. 5 to FORM S-1)
• 5 — Amendment Number (FORM S-1 REGISTRATION STATEMENT)
• 2834 — SIC Code (Primary Standard Industrial Classification Code Number)
• 86-3329066 — IRS Number (I.R.S. Employer Identification Number)

Key Players & Entities

• FibroBiologics Inc. (company) — Registrant name
• Pete O'Heeron (person) — Chief Executive Officer
• Norton Rose Fulbright US LLP (company) — Legal counsel
• Brian Fenske (person) — Legal counsel contact
• Delaware (jurisdiction) — State of incorporation
• Houston, Texas (location) — Principal executive offices
• 281-671-5152 (phone_number) — Business phone number
• 333-275361 (registration_number) — SEC file number

Forward-Looking Statements

• FibroBiologics Inc. will complete its public offering and begin trading on a major exchange. (FibroBiologics Inc.) — medium confidence, target: 2024-12-31
• The company will successfully raise capital to fund its pharmaceutical research and development. (FibroBiologics Inc.) — medium confidence, target: 2025-01-12

FAQ

Industry Context

FibroBiologics operates within the pharmaceutical preparations industry, focusing on the development and commercialization of regenerative medicine products.

Regulatory Implications

The company is subject to the regulations of the Securities Act of 1933, which governs the registration and sale of securities in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed information on the securities being registered and the terms of the offering.
2. Track subsequent SEC filings for updates on the registration effectiveness, pricing, and any material developments.
3. Analyze the company's business strategy and financial projections once they are disclosed in more detail in future filings.

Year-Over-Year Comparison

This is an amendment (No. 5) to a previously filed S-1 registration statement, indicating ongoing adjustments and updates to the offering details.

Key Financial Figures

• $6.76 — cement, at a price of the equivalent of $6.76 per share as to the equivalent of 318,0
• $18.00 — t prices ranging from the equivalent of $18.00 to the equivalent of $20.00 per share a
• $20.00 — uivalent of $18.00 to the equivalent of $20.00 per share as to the equivalent of 64,07

Filing Documents

• forms-1a.htm (S-1/A) — 2780KB
• ex23-2.htm (EX-23.2) — 5KB
• fdrs_001.jpg (GRAPHIC) — 4KB
• drs_1.jpg (GRAPHIC) — 18KB
• drs_2.jpg (GRAPHIC) — 18KB
• formdrs_005.jpg (GRAPHIC) — 6KB
• formdrs_006.jpg (GRAPHIC) — 7KB
• fdrs_004.jpg (GRAPHIC) — 18KB
• fdrs_005.jpg (GRAPHIC) — 15KB
• fdrs_006.jpg (GRAPHIC) — 11KB
• fdrs_007.jpg (GRAPHIC) — 12KB
• 0001493152-24-002195.txt (&nbsp;) — 2938KB

RISK FACTORS

RISK FACTORS 9 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 62 MARKET AND INDUSTRY DATA 63 TRADEMARKS, SERVICE MARKS AND TRADENAMES 64

USE OF PROCEEDS

USE OF PROCEEDS 65 DIVIDEND POLICY 65 CAPITALIZATION 65 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 66

BUSINESS

BUSINESS 77 MANAGEMENT 101 EXECUTIVE AND DIRECTOR COMPENSATION 108 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 113 PRINCIPAL AND REGISTERED STOCKHOLDERS 114

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 116 SHARES ELIGIBLE FOR FUTURE SALE 120 SALE PRICE HISTORY OF OUR CAPITAL STOCK 121 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 121 PLAN OF DISTRIBUTION 12 6 LEGAL MATTERS 129 EXPERTS 129 WHERE YOU CAN FIND ADDITIONAL INFORMATION 12 9 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor any of the Registered Stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor any of the Registered Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Registered Stockholders are offering to sell, and seeking offers to buy, shares of their common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor any of the Registered Stockholders have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Registered Stock

View Full Filing

View this S-1/A filing on SEC EDGAR